| 1 |
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke [J]. N Engl J Med, 1995, 333(24): 1581-1587.
|
| 2 |
Ye Q, Zhai F, Chao B, et al. Rates of intravenous thrombolysis and endovascular therapy for acute ischaemic stroke in China between 2019 and 2020 [J]. Lancet Reg Health West Pac, 2022, 21: 100406.
|
| 3 |
Ebinger M, Siegerink B, Kunz A, et al. Berlin_PRehospital Or Usual Delivery in stroke care (B_PROUD) study group. Association between dispatch of mobile stroke units and functional outcomes among patients with acute ischemic stroke in Berlin [J]. JAMA, 2021, 325(5): 454-466.
|
| 4 |
Grotta JC, Yamal JM, Parker SA, et al. Prospective, multicenter, controlled trial of mobilestroke units [J]. N Engl J Med, 2021, 385(11): 971-981.
|
| 5 |
Kim J, Easton D, Zhao H, et al. Economic evaluation of the Melbourne Mobile Stroke Unit [J]. Int J Stroke, 2021, 16(4): 466-475.
|
| 6 |
Lund UH, Stoinska-Schneider A, Larsen K, et al. Cost-effectiveness of mobile stroke unit care in Norway [J]. Stroke, 2022, 53(10): 3173-3181.
|
| 7 |
国家卫健委脑卒中防治工程委员会专家委员会, 中华医学会急诊分会, 中国卒中学会急救医学分会, 等. 中国5G移动卒中单元院前诊疗管理指南 [J]. 中华神经医学杂志, 2023, 22(1): 2-17.
|
| 8 |
王春娟, 霍晓川, 冀瑞俊, 等. 急性缺血性卒中再灌注治疗医疗质量评价与改进专家建议 [J]. 中国卒中杂志, 2021, 16(7): 705-715.
|
| 9 |
Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct [J]. N Engl J Med, 2018, 378(1): 11-21.
|
| 10 |
Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging [J]. N Engl J Med, 2018, 378(8): 708-718.
|
| 11 |
Regenhardt RW, González RG, He J, et al. Symmetric CTA collaterals identify patients with slow-progressing stroke likely to benefit from late thrombectomy [J]. Radiology, 2022, 302(2): 400-407.
|
| 12 |
Uniken Venema SM, Dankbaar JW, van der Lugt A, et al. Cerebral collateral circulation in the era of reperfusion therapies for acute ischemic stroke [J]. Stroke, 2022, 53(10): 3222-3234.
|
| 13 |
Olivot JM, Heit JJ, Mazighi M, et al. What predicts poor outcome after successful thrombectomy in early time window? [J]. J Neurointerv Surg, 2022, 14(11): 1051-1055.
|
| 14 |
Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke [J]. N Engl J Med, 2019, 380(19): 1795-1803.
|
| 15 |
Thomalla G, Simonsen CZ, Boutitie F, et al. MRI-guided thrombolysis for stroke with unknown time of onset [J]. N Engl J Med, 2018, 379(7): 611-622.
|
| 16 |
Tsivgoulis G, Katsanos AH, Malhotra K, et al. Thrombolysis for acute ischemic stroke in the unwitnessed or extended therapeutic time window [J]. Neurology, 2020, 94(12): e1241-e1248.
|
| 17 |
中华医学会神经病学分会. 中国急性缺血性脑卒中诊治指南2018 [J]. 中华神经科杂志, 2018, 51(9): 666-682.
|
| 18 |
Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke [J]. N Engl J Med, 2018, 378(17): 1573-1582.
|
| 19 |
Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial [J]. Lancet, 2022, 400(10347): 161-169.
|
| 20 |
Bivard A, Zhao H, Churilov L, et al. TASTE-A collaborators. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial [J]. Lancet Neurol, 2022, 21(6): 520-527.
|
| 21 |
Roaldsen MB, Eltoft A, Wilsgaard T, et al. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial [J]. Lancet Neurol, 2023, 22(2): 117-126.
|
| 22 |
Singer OC, Kurre W, Humpich MC, et al. Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS [J]. Stroke, 2009, 40(8): 2743-2748.
|
| 23 |
Cheng B, Boutitie F, Nickel A, et al. WAKE-UP (Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke Trial) investigators and administrative staff are as follows: quantitative signal intensity in fluid-attenuated inversion recovery and treatment effect in the WAKE-UP Trial [J]. Stroke, 2020, 51(1): 209-215.
|
| 24 |
Hill MD, Goyal M, Menon BK, et al. ESCAPE-NA1 Investigators. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial [J]. Lancet, 2020, 395(10227): 878-887.
|
| 25 |
Wahlgren N, Thorén M, Höjeberg B, et al. Randomized assessment of imatinib in patients with acute ischemic stroke treated with intravenous thrombolysis [J]. J Intern Med, 2017, 281(3): 273-283.
|
| 26 |
Xu J, Wang A, Meng X, et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase iii, randomized, double-blind, comparative trial [J]. Stroke, 2021, 52(3): 772-780.
|
| 27 |
Wang M, Feng Y, Yuan Y, et al. Use of l-3-n-Butylphthalide within 24 h after intravenous thrombolysis for acute cerebral infarction [J]. Complement Ther Med, 2020, 52: 102442.
|